menu
    • menu
    [{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2013","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2011","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"University of Oxford","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"UNITED KINGDOM","productType":"Miscellaneous","year":"2012","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Steba Biotech \/ Steba Biotech","highestDevelopmentStatusID":"7","companyTruncated":"Steba Biotech \/ Steba Biotech"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"PrimeVigilance Ltd | Icon Plc","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Steba Biotech \/ PrimeVigilance Ltd | Icon Plc","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ PrimeVigilance Ltd | Icon Plc"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Miscellaneous","year":"2021","type":"Inapplicable","leadProduct":"Padeliporfin","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase III","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Steba Biotech \/ Undisclosed","highestDevelopmentStatusID":"10","companyTruncated":"Steba Biotech \/ Undisclosed"},{"orgOrder":0,"company":"Steba Biotech","sponsor":"International Drug Development Institute | PrimeVigilance Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"LUXEMBOURG","productType":"Plant Extract\/Herbal","year":"2019","type":"Inapplicable","leadProduct":"Tookad","moa":"benzoporphyrin derivatives","graph1":"Oncology","graph2":"Phase IV","graph3":"Steba Biotech","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Steba Biotech \/ International Drug Development Institute | PrimeVigilance Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Steba Biotech \/ International Drug Development Institute | PrimeVigilance Ltd"}]

    Find Clinical Drug Pipeline Developments & Deals by Steba Biotech

    Menu

    Steba Biotech

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Steba Biotech Treats First Patient in Pivotal ENLIGHTED Study of Padeliporfin ImPACT in Low Grade Upper Tract ...

                            Details : The ENLIGHTED study aims to recruit 100 patients with low-grade UTUC in either the kidney or the ureter. The patients will be treated with Padeliporfin ImPACT in two phases, induction treatment and maintenance treatment, and will be followed up for 1-5 y...

                            Product Name : Padeliporfin ImPACT

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 20, 2021

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            FDA Grants Fast Track Designation to Padeliporfin ImPACT for Steba Biotech

                            Details : This swiftly follows clearance of the Investigational New Drug (IND) application granted in December 2020 allowing initiation of the pivotal Phase 3 clinical trial of padeliporfin ImPACT in patients with low-grade UTUC, expected to begin enrollment in Q1...

                            Product Name : Padeliporfin ImPACT

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 15, 2021

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : PrimeVigilance Ltd | Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ENdoluminal LIGHT ActivatED Treatment of Upper Tract Urothelial Cancer (ENLIGHTED) Study

                            Details : Padeliporfin is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Carcinoma, Transitional Cell.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 06, 2020

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : PrimeVigilance Ltd | Icon Plc

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of Efficacy of TOOKAD® (VTP) Versus Active Surveillance for Intermediate Risk Localized Prostate...

                            Details : Tookad (Padeliporfin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Tookad

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 13, 2020

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tookad

                            Therapeutic Area : Oncology

                            Study Phase : Phase IV

                            Sponsor : International Drug Development Institute | PrimeVigilance Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of Erectile Dysfunction, Urinary Incontinence and Related QoL After TOOKAD® VTP for Low Risk Prostate...

                            Details : Tookad is a Plant Extract/Herbal drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Plant Extract/Herbal

                            Upfront Cash : Inapplicable

                            February 21, 2019

                            Lead Product(s) : Tookad

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase IV

                            Sponsor : International Drug Development Institute | PrimeVigilance Ltd

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Efficacy, Safety and Quality of Life After TOOKAD® Soluble (VTP) for Intermediate Risk Prostat...

                            Details : Tookad (Padeliporfin) is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : Tookad

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 20, 2017

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy,Safety and Quality of Life After TOOKAD® Soluble VTP for Localized Prostate Cancer

                            Details : TOOKAD (WST11) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : TOOKAD

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            June 11, 2013

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Recipient : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vascular Targeted Photodynamic Therapy T1a Renal Tumours

                            Details : WST11 is a Other Small Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Kidney Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            April 06, 2012

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : University of Oxford

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed

                            Steba Biotech

                            Luxembourg arrow
                            AllPack Indonesia
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance.

                            Details : TOOKAD (WST11) is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Prostatic Neoplasms.

                            Product Name : TOOKAD

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            March 09, 2011

                            Lead Product(s) : Padeliporfin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth